Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TxD ADC
- Development stage
- Preclinical
- Lead developer
- Manhattan Biosolutions
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TxD ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Manhattan BioSolutions for the treatment of advanced cancers. The candidate utilizes a proprietary taxoid-class payload, which acts as a microtubule-targeting agent to induce cell cycle arrest and apoptosis. This cytotoxic warhead is conjugated to a tumor-targeting antibody via the company's proprietary legumain-activated linker technology. This linker is designed to release the payload specifically within the tumor microenvironment, where the protease legumain (an asparaginyl endopeptidase) is overexpressed. The program is being advanced in collaboration with Dr. Iwao Ojima's laboratory at Stony Brook University and aims to enhance therapeutic potency while overcoming common resistance mechanisms in solid tumors.
- Other names
- Taxoid ADC
02
Targets
LGMN (Legumain)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TxD ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TxD ADC.